Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans

Cancer Research

Volumn 58, Issue 11, 1998, Pages 2410-2416

  Van Tellingen, Olaf ^a   Nooijen, Willem J ^a   Schaaf, Larry J ^d   Van Der Valk, Martin ^a   Van Asperen, Judith ^a   Henrar, Roland E C ^c   Beijnen, Jos H ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARZELESIN; U 76074; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LETHAL DOSE; MALE; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOFURANS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HEMATOPOIETIC STEM CELLS; HUMANS; INDOLES; MALE; MICE; MODELS, CHEMICAL; PRODRUGS; RATS; REPRODUCIBILITY OF RESULTS;

EID: 0032101165     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. McGovren, J. P., Clarke, G. L., Pratt, H. A., and DeKoning, T. F. Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J. Antibiot. (Tokyo), 37: 63-70, 1984.
2. Hurley, L. H., Reynolds, V. L., Swenson, D. H., Petzold, G. L., and Scahill, T. A. Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science (Washington DC), 226: 843-844, 1984.
3. Swenson, D. H., Li, Hurley, L. H., Rokem, J. S., Petzold, G. L., Dayton, B. D., Wallace, T. L., Lin, A. H., and Krueger, W. C. Mechanism of interaction of CC-1065 (NSC 298223) with DNA. Cancer Res., 42: 2821-2828, 1982.
4. Hightower, R. D., Sevin, B. U., Perras, J., Nguyen, H., Angioli, R., Untch, M., and Averette, H. In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines. Cancer Invest., 11: 276-282, 1993.
5. Li, L. H., Kelly, R. C., Warpehoski, M. A., McGovren, J. P., Gehhard, I., and DeKoning, T. F. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065. Invest. New Drugs, 9: 137-148, 1991.
6. Walker, D. L., Reid, J. M., and Ames, M. M. Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065. Cancer Chemother. Pharmacol., 34: 317-322, 1994.
7. Li, L. H., DeKoning, T. F., Kelly, R. C., Krueger, W. C., McGovren, J. P., Padbury, G. E., Petzold, G. L., Wallace, T. L., Ouding, R. J., Prairie, M. D., and Gebhard, I. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res., 52: 4904-4913, 1992.
8. Shamdas, G. J., Alberts, D. S., Modiano, M., Wiggins, C., Power, J., Kasunic, D. A., Elfring, G. L., and Earhart, R. H. Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anticancer Drugs, 5: 10-14, 1994.
9. Fleming, G. F., Ratain, M. J., O'Brien, S. M., Schilsky, R. L., Hoffman, P. C., Richards, J. M., Vogelzang, N. J., Kasunic, D. A., and Earhart, R. H. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J. Natl. Cancer Inst., 86: 368-372, 1994.
10. Lednicer, D., Flora, K., Vishnuvajjala, R., and Turner, G. Ready to use bizelesin. Ann. Oncol., 5 (Suppl. 5): 168, 1994.
11. McGovren, J. P., Padbury, G. E., Petzold, G. L., Li, L. H., DeKoning, T. F., Ouding, R. J., and Larson, P. G. Kinetics of tumor and normal tissue DNA alkylation by cyclopropylpyrroloindole (CPI) analogs U-73795 (adozelesin) and U-80244 in the mouse. Ann. Oncol., 3 (Suppl. 1): 189, 1992.
12. Wolff, I., Bench, K., Beijnen, J. H., Bruntsch, U., Cavalli, F., De Jong, J., Groot, Y., van Tellingen, O., Wanders, J., and Sessa, C. Phase I Clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. Clin. Cancer Res., 2: 1717-1723, 1996.
13. van Tellingen, O., Pels, E. M., Henrar, R. E. C., Schaaf, L. J., Padbury, G. E., Beijnen, J. H., and Nooijen, W. J. Fully automated high-performance liquid Chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma. J. Chromalogr., 652: 51-58, 1994.
14. Jonkman-de Vries, J. D., de Graaff-Teulen, M. J., Henrar, R. E. C., Kettenes-van den Bosch, J. J., Bult, A., and Beijnen, J. H. Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzclesin (U-80,244). Invest. New Drugs, 12: 303-314, 1994.
15. Harrison, P. T. An ethanol-acetic acid-formol saline fixative for routine use with special application to the fixation of non-perfused rat lung. Lab. Anim., 18: 325-331, 1984.
16. van Tellingen, O., Punt, C. J. A., Awada, A., Wagener, D. J. T., Piccart, M. J., Groot, Y., Schaaf, L. J., Henrar, R. E., Nooijen, W. J., and Beijnen, J. H. A clinical pharmacokinetic study of carzelesin given by a short intravenous infusion in a Phase I study. Cancer Chemother. Pharamcol., 41: 377-384, 1998.
17. Proost, J. H., and Mcijer, D. K. F. MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput. Biol. Med., 22: 155-160, 1992.
18. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep., 50: 219-244, 1966.
19. Collins, J. M., Zaharko, D. S., Dedriek, R. L., and Chabner, B. A. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep., 70: 73-80, 1986.
20. Gianni, L., Vigano, L., Surbone, A., Ballinari, D., Casali, P., Tarella, C., Collins, J. M., and Bonadonna, G. Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials [see comments]. J. Natl. Cancer Inst., 82: 469-477, 1990.
21. Volpe, D. A., Tomaszewski, J. E., Parchment, R. E., Garg, A., Flora, K. P., Murphy, M. J., and Grieshaber, C. K. Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Cancer. Chemother. Pharmacol., 39: 143-149, 1996.
22. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, and Houghton, J. A. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 36: 45-52, 1995.